Organon announced on March 8, 2025, new results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study for VTAMA (tapinarof) cream, 1%. The findings demonstrated that atopic dermatitis (AD) disease activity remained mild in adults and children aged two years and older who achieved treatment success and subsequently entered a treatment-free interval.
Patients in the study maintained a validated Investigator Global Assessment for AD (vIGA-AD) score of 2 (mild) at the end of the first treatment-free interval, which lasted an average of 79.8 consecutive days. Itch, assessed by the Peak Pruritus Numerical Rating Scale, remained low with a mean weekly score of 2.9.
These data reinforce the efficacy of VTAMA cream in atopic dermatitis, including the durability of effect, and suggest the possibility of over two months of relief without needing to reapply treatment. This supports the product's value proposition following its FDA approval for AD in December 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.